A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
Recruiting · NCT06785116 · Registry updated 2026-03-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) | Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, cardiovascular disorder, hypertension, pregnancy-induced, hypertensive disorder, preeclampsia, pregnancy disorder, vascular disorder | Recruiting | Phase 4 | 2026-03-04 | NCT06785116 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Michigan | Ann Arbor | United States | 538 |